The use of femoral struts and impacted cancellous bone allograft in patients with severe femoral bone loss who undergo revision total hip replacement A THREE- TO NINE-YEAR FOLLOW-UP
Italian Hospital of Buenos Aires, The Hip Surgery Unit, Institute of Orthopaedics Carlos E. Ottolenghi, Potosi 4247, Buenos Aires, 1199, Argentina. The Bone & Joint Journal
(Impact Factor: 3.31).
02/2012; 94(2):167-72. DOI: 10.1302/0301-620X.94B2.27296
We determined the midterm survival, incidence of peri-prosthetic fracture and the enhancement of the width of the femur when combining struts and impacted bone allografts in 24 patients (25 hips) with severe femoral bone loss who underwent revision hip surgery. The pre-operative diagnosis was aseptic loosening in 16 hips, second-stage reconstruction in seven, peri-prosthetic fracture in one and stem fracture in one hip. A total of 14 hips presented with an Endoklinik grade 4 defect and 11 hips a grade 3 defect. The mean pre-operative Merle D'Aubigné and Postel score was 5.5 points (1 to 8). The survivorship was 96% (95% confidence interval 72 to 98) at a mean of 54.5 months (36 to 109). The mean functional score was 17.3 points (16 to 18). One patient in which the strut did not completely bypass the femoral defect was further revised using a long cemented stem due to peri-prosthetic fracture at six months post-operatively. The mean subsidence of the stem was 1.6 mm (1 to 3). There was no evidence of osteolysis, resorption or radiolucencies during follow-up in any hip. Femoral width was enhanced by a mean of 41% (19% to 82%). A total of 24 hips had partial or complete bridging of the strut allografts. This combined biological method was associated with a favourable survivorship, a low incidence of peri-prosthetic fracture and enhancement of the width of the femur in revision total hip replacement in patients with severe proximal femoral bone loss.
Available from: Michael Jagodzinski
[Show abstract] [Hide abstract]
ABSTRACT: Treating segmental long-bone defects remains a major challenge. For defects >3 cm, segmental transport represents the gold standard, even though the method is time consuming and afflicted with several complications. The aim of this study was to evaluate healing of such defects after grafting an osteogenic scaffold previously seeded with stem cell concentrate.
We evaluated five patients with segmental long-bone defects (3-14 cm) treated with bone marrow aspirate concentrates (BMAC) seeded onto a bovine xenogenous scaffold. The healing process was monitored by X-rays and positron emission tomography-computed tomography (PET-CT) three months after surgery.
Centrifugation led to a concentration of leukocytes by factor 8.1 ± 7.5. Full weight bearing was achieved 11.3 ± 5.0 weeks after surgery. PET analysis showed an increased influx of fluoride by factor 8.3 ± 6.4 compared with the contralateral side (p < 0.01). Bone density in the cortical area was 75 ± 16 % of the contralateral side (p < 0.03). The patient with the largest defect sustained an implant failure in the distal femur and finally accomplished therapy by segmental transport. He also had the lowest uptake of fluoride of the patient collective (2.2-fold increase).
Stem cell concentrates can be an alternative to segmental bone transport. Further studies are needed to compare this method with autologous bone grafting and segmental transport.
International Orthopaedics 09/2013; 37(11). DOI:10.1007/s00264-013-2087-y · 2.11 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Thermodisinfection of human femoral heads from living donors harvested during hip joint replacement is an established processing procedure. This study was designed to examine the influence of heat sterilization on pull out strength of cancellous bone and storage at different temperatures up to 2 years since we had previously studied the storage of unprocessed cancellous bone. Porcine cancellous bone resembling human bone structure was obtained from 140 proximal humerus of 6-8 months old piglets. Pull out strength of screws after thermodisinfection was compared with unprocessed cancellous bone and tested immediately and after 6, 12 and 24 months of storage at -20 and -80 °C. A three-way ANOVA was performed and significance level was 5 %. The thermodisinfected bone showed a pull out force of 2729 N (1657-3568 N). The reduction of pull out strength compared with unprocessed bone over all periods of storage was 276 N on average with 95 % confidence interval ranging from 166 N to 389 N (p < 0.0001). Different freezing temperatures did not influence this mechanic property within 24 months storage and showed no difference compared with fresh frozen bone. Thermodisinfection of cancellous bone preserves tensile strength necessary for clinical purposes. The storage at -20 °C for at least 2 years did not show relevant decrease of pull out strength compared with -80 °C without difference between thermodisinfected and fresh frozen bone. The increase of the storage temperature to -20 °C for at least 2 years should be considered.
Cell and Tissue Banking 04/2014; 16(1). DOI:10.1007/s10561-014-9442-0 · 1.25 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Following the increasing number of total hip arthroplasties, the amount of hip revision procedures continue to rise. Careful patient selection and bone loss evaluation is crucial for a correct management of femoral revision procedures. The key point in femoral revision is to obtain a reliable primary stability of the stem, with the least invasive implant as possible, to preserve and if possible to restore the bone stock. In this article we present the indications and the techniques for the femoral revisions most commonly used in Europe, referring to the evidence in the literature and our personal experiences.
Hip international: the journal of clinical and experimental research on hip pathology and therapy 06/2014; 24(Suppl 10). DOI:10.5301/hipint.5000174 · 0.76 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.